The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Leading specialists discuss the increasing prevalence of colorectal diseases in India, highlighting modern treatment ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) have received a consensus recommendation of “Buy” ...

The virus is similar to Ebola and symptoms include 'unexplained bleeding', vomiting and diarrhoea - an outbreak has been ...

The virus is similar to Ebola and symptoms include 'unexplained bleeding', vomiting and diarrhoea - an outbreak has been ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion in 2024 and an impressive US$3.05 billion by 2029. Market ...

PORTLAND, OR, UNITED STATES, February 15, 2025 /EINPresswire / -- Ankylosing spondylitis (AS) is a chronic inf ...